Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study by Oxford and Sheffield researchers using a cutting-edge method of imaging has identified persistent damage to the lungs of COVID-19 patients at least three months after they were discharged from hospital, and for some patients even longer.

CT scan of lungs © Department on Oncology, University of Oxford

This damage was not detected by routine CT scans and clinical tests, and the patients would consequently normally be told their lungs are normal.

Further early research by the team has shown that patients who have not been hospitalised with COVID-19 but who are experiencing long-term breathlessness may have similar damage in their lungs, and a larger study is needed to confirm this.

In a paper published in Radiology, the world’s leading radiology journal, the researchers from Oxford and Sheffield said that hyperpolarised xenon MRI (XeMRI) scans had found abnormalities in the lungs of some COVID-19 patients more than three months – and in some cases, nine months - after leaving hospital, when other clinical measurements were normal.

The study’s Principal Investigator Professor Fergus Gleeson, Professor of Radiology in the Department of Oncology, (University of Oxford) and Consultant Radiologist at Oxford University Hospitals (OUH) NHS Foundation Trust, said: “Many COVID-19 patients are still experiencing breathlessness several months after being discharged from hospital, despite their CT scans indicating that their lungs are functioning normally. 

“Our follow-up scans using hyperpolarised xenon MRI have found that abnormalities not normally visible on regular scans are indeed present, and these abnormalities are preventing oxygen getting into the bloodstream as it should in all parts of the lungs.”

Read the full story on the NIHR Oxford Biomedical Research Centre website

Similar stories

Oxford University academics recognised in Queen’s Birthday Honours

The pioneering work of members of the University, including research into tackling the Coronavirus pandemic, has been recognised in The Queen's Birthday Honours List.

Two Oxford Professors elected as EMBO Members

Professor Robert Klose and Professor Ervin Fodor are two of 64 life scientists to be elected to The European Molecular Biology Organization (EMBO).

Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

AI endoscopy enables 3D surface measurements of pre-cancerous condition in oesophagus

Clinicians and engineers in Oxford have begun using artificial intelligence alongside endoscopy to get more accurate readings of the pre-cancerous condition Barrett’s oesophagus and so determine patients most at risk of developing cancer.

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

New Head of the Department of Psychiatry – Professor Belinda Lennox

Professor Belinda Lennox has been welcomed to the role of Head of the Department of Psychiatry at the University of Oxford and will take over leadership in October 2021.